Halozyme Therapeutics Misses Q4 Earnings Expectations

Got story updates? Submit your updates here. ›

Halozyme Therapeutics (NASDAQ:HALO), a biopharmaceutical company focused on drug delivery technologies, reported its fourth-quarter financial results on Tuesday. The company reported a loss of $0.24 per share, missing analysts' consensus estimate of $1.92 EPS by $2.16. Halozyme's revenue for the quarter was $451.77 million, up 51.6% year-over-year but slightly above the $446.13 million expected by analysts.

Why it matters

Halozyme's earnings miss and larger-than-expected quarterly loss triggered near-term selling pressure on the stock, as investors grew concerned about the company's financial performance and profitability. However, the company reported record full-year 2025 revenue and provided strong 2026 guidance, suggesting continued growth and revenue visibility.

The details

Halozyme reported a net loss of $0.24 per share for the fourth quarter, compared to analysts' expectations of $1.92 EPS. The company's revenue of $451.77 million was up 51.6% year-over-year but slightly above the $446.13 million expected by analysts. Halozyme attributed the revenue growth to strong performance of its ENHANZE-enabled products, including DARZALEX SC, Phesgo, and VYVGART Hytrulo.

• Halozyme reported its fourth-quarter financial results on Tuesday, February 18, 2026.

What’s next

The company's 2026 guidance, which calls for total revenue of $1.71-$1.81 billion and non-GAAP EPS of $7.75-$8.25, will be closely watched by investors to see if Halozyme can deliver on its growth projections.